Risk of regorafenib-induced cardiovascular events in patients with solid tumors: A systematic review and meta-analysis.

ABSTRACT:

Background

The present comparative meta-analysis was conducted to evaluate the cardiovascular events of regorafenib in patients with solid tumors.

Methods

Eligible studies from MEDLINE, Google Scholar, Cochrane Library, Clinical key, EBSCO publishing and Ovid, which had reported cardiovascular adverse events potentially caused by regorafenib were absorbed. Data of clinical characteristics and cardiovascular events including hypertension, hemorrhage, thrombosis, and heart failure were extracted from selected literatures for the final analysis. Pooled analysis of cardiovascular adverse events was developed by relative risks (RRs) and corresponding 95% confidence intervals (CIs) with software STATA 13.0 and RevMan 5.3.

Results

Thirty studies including 3813 patients were

SUBMITTER: Chen J 

PROVIDER: S-EPMC6203579 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature